http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 07:32:58 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Compass+Therapeutics+%28CMPX%29+Reiterated+at+Buy+by+Stifel+After+ASCO+Presentation/26579273.html <p>Stifel analyst Stephen Willey reiterated a Buy rating and $6.00 price target on Compass Therapeutics (NASDAQ: CMPX).</p><p>The analyst commented, " We believe the presentation of P1 singleagent CTX-8371 (PD-1xPD-L1 bispecific) dose-escalation data at this weekend’s ASCO meeting was minimally incremental given the recent publication of ASCO abstracts and prior qualitative management commentary re: safety/efficacy. We believe the durability of those responses observed to date in a heavily pretreated/IO-experienced patient population are impressive and believe granular safety/ tolerability data highlighting an absence of immune-mediated TRAEs highlights the unique mechanism of action anchoring CTX-8371 to the tumor microenvironment (vs. systemic inhibition within http://www.streetinsider.com/Analyst+Comments/Compass+Therapeutics+%28CMPX%29+Reiterated+at+Buy+by+Stifel+After+ASCO+Presentation/26579273.html Mon, 01 Jun 2026 07:32:58 -0400 CMPX http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Participate+in+Upcoming+June+Investor+Events/26561126.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June.</p> <p><strong>Details are as follows:</strong></p> <p><strong>Jefferies Global Healthcare Conference</strong><br/><strong>Date:</strong> Thursday, June 4, 2026 <br/><strong>Time:</strong> 8:45 AM ET<br/><strong>Webcast Link: </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Bde3x5fD8-IQlJ59dDB_KIgPHq3iv2DRmDIqMKW90DBZ9KhcoQv3Mv1-V4K1zh700iZ3XIoHRrtAmiDQQQcAdOEtTbrY221I7yk573IrAkKi75Yt_AvSMtqQDxbcxIMQcZd7cfSQGVyaZgwaSqHmm-Eh_LFB7POHniN53pI3IosTc2NHErKeDV4sTAboEIbR" rel="nofollow" target="_blank">https://cmpx.info/jefferies</a></p> <p><strong>Goldman Sachs 47th Annual Global Healthcare Conference</strong><br/><strong>Date:</strong> Tuesday, June 9, 2026 <br/><strong>Time:</strong> 8:00 AM ET<br/><strong>Webcast Link:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Bde3x5fD8-IQlJ59dDB_KLwCklWAn0KS-HqVAt438neA5z52-9sNyjEjCHpEnnyjSHO87OhEc3pPe2kKP9LKeqTJTA6lZknmrfVFN2-cW5xel9KNsWMgCzF2vKVWzea4Oz9Ecx-iiaVhfECpgsAxG-dV34xut4DjR6oMqe2NKqc=" rel="nofollow" target="_blank">https://cmpx.info/gs</a></p> <p><strong>Virtual/Replay availability: </strong>Presentations will be archived on Compass’ <a http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Participate+in+Upcoming+June+Investor+Events/26561126.html Thu, 28 May 2026 07:30:00 -0400 CMPX O.49925668 http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Participate+in+Upcoming+June+Investor+Events/26561126.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June.</p> <p><strong>Details are as follows:</strong></p> <p><strong>Jefferies Global Healthcare Conference</strong><br/><strong>Date:</strong> Thursday, June 4, 2026 <br/><strong>Time:</strong> 8:45 AM ET<br/><strong>Webcast Link: </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Bde3x5fD8-IQlJ59dDB_KIgPHq3iv2DRmDIqMKW90DBZ9KhcoQv3Mv1-V4K1zh700iZ3XIoHRrtAmiDQQQcAdOEtTbrY221I7yk573IrAkKi75Yt_AvSMtqQDxbcxIMQcZd7cfSQGVyaZgwaSqHmm-Eh_LFB7POHniN53pI3IosTc2NHErKeDV4sTAboEIbR" rel="nofollow" target="_blank">https://cmpx.info/jefferies</a></p> <p><strong>Goldman Sachs 47th Annual Global Healthcare Conference</strong><br/><strong>Date:</strong> Tuesday, June 9, 2026 <br/><strong>Time:</strong> 8:00 AM ET<br/><strong>Webcast Link:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Bde3x5fD8-IQlJ59dDB_KLwCklWAn0KS-HqVAt438neA5z52-9sNyjEjCHpEnnyjSHO87OhEc3pPe2kKP9LKeqTJTA6lZknmrfVFN2-cW5xel9KNsWMgCzF2vKVWzea4Oz9Ecx-iiaVhfECpgsAxG-dV34xut4DjR6oMqe2NKqc=" rel="nofollow" target="_blank">https://cmpx.info/gs</a></p> <p><strong>Virtual/Replay availability: </strong>Presentations will be archived on Compass’ <a http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Participate+in+Upcoming+June+Investor+Events/26561126.html Thu, 28 May 2026 07:30:00 -0400 CMPX O.49925668 http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Participate+in+Upcoming+June+Investor+Events/26561126.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June.</p> <p><strong>Details are as follows:</strong></p> <p><strong>Jefferies Global Healthcare Conference</strong><br/><strong>Date:</strong> Thursday, June 4, 2026 <br/><strong>Time:</strong> 8:45 AM ET<br/><strong>Webcast Link: </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Bde3x5fD8-IQlJ59dDB_KIgPHq3iv2DRmDIqMKW90DBZ9KhcoQv3Mv1-V4K1zh700iZ3XIoHRrtAmiDQQQcAdOEtTbrY221I7yk573IrAkKi75Yt_AvSMtqQDxbcxIMQcZd7cfSQGVyaZgwaSqHmm-Eh_LFB7POHniN53pI3IosTc2NHErKeDV4sTAboEIbR" rel="nofollow" target="_blank">https://cmpx.info/jefferies</a></p> <p><strong>Goldman Sachs 47th Annual Global Healthcare Conference</strong><br/><strong>Date:</strong> Tuesday, June 9, 2026 <br/><strong>Time:</strong> 8:00 AM ET<br/><strong>Webcast Link:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Bde3x5fD8-IQlJ59dDB_KLwCklWAn0KS-HqVAt438neA5z52-9sNyjEjCHpEnnyjSHO87OhEc3pPe2kKP9LKeqTJTA6lZknmrfVFN2-cW5xel9KNsWMgCzF2vKVWzea4Oz9Ecx-iiaVhfECpgsAxG-dV34xut4DjR6oMqe2NKqc=" rel="nofollow" target="_blank">https://cmpx.info/gs</a></p> <p><strong>Virtual/Replay availability: </strong>Presentations will be archived on Compass’ <a http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Participate+in+Upcoming+June+Investor+Events/26561126.html Thu, 28 May 2026 07:30:00 -0400 CMPX O.49925668 http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Participate+in+Upcoming+June+Investor+Events/26561126.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June.</p> <p><strong>Details are as follows:</strong></p> <p><strong>Jefferies Global Healthcare Conference</strong><br/><strong>Date:</strong> Thursday, June 4, 2026 <br/><strong>Time:</strong> 8:45 AM ET<br/><strong>Webcast Link: </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Bde3x5fD8-IQlJ59dDB_KIgPHq3iv2DRmDIqMKW90DBZ9KhcoQv3Mv1-V4K1zh700iZ3XIoHRrtAmiDQQQcAdOEtTbrY221I7yk573IrAkKi75Yt_AvSMtqQDxbcxIMQcZd7cfSQGVyaZgwaSqHmm-Eh_LFB7POHniN53pI3IosTc2NHErKeDV4sTAboEIbR" rel="nofollow" target="_blank">https://cmpx.info/jefferies</a></p> <p><strong>Goldman Sachs 47th Annual Global Healthcare Conference</strong><br/><strong>Date:</strong> Tuesday, June 9, 2026 <br/><strong>Time:</strong> 8:00 AM ET<br/><strong>Webcast Link:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Bde3x5fD8-IQlJ59dDB_KLwCklWAn0KS-HqVAt438neA5z52-9sNyjEjCHpEnnyjSHO87OhEc3pPe2kKP9LKeqTJTA6lZknmrfVFN2-cW5xel9KNsWMgCzF2vKVWzea4Oz9Ecx-iiaVhfECpgsAxG-dV34xut4DjR6oMqe2NKqc=" rel="nofollow" target="_blank">https://cmpx.info/gs</a></p> <p><strong>Virtual/Replay availability: </strong>Presentations will be archived on Compass’ <a http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Participate+in+Upcoming+June+Investor+Events/26561126.html Thu, 28 May 2026 07:30:00 -0400 CMPX O.49925668 http://www.streetinsider.com/FDA/Compass+Therapeutics+reports+phase+1+data+for+CTX-8371+at+ASCO+meeting/26536484.html <p>Compass Therapeutics Inc. (NASDAQ: CMPX) announced it will present phase 1 clinical data for CTX-8371 at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.</p> <p>The study evaluated CTX-8371, a dual checkpoint blocker targeting PD-1 and PD-L1, in 15 patients with advanced malignancies who had previously received immune checkpoint inhibitor treatment. Three patients achieved responses: one with triple-negative breast cancer showed greater than 90% reduction in target tumor lesions, one with Hodgkin lymphoma achieved a partial metabolic response, and one with non-small cell lung cancer achieved complete resolution of target lesions.</p> <p>At the two http://www.streetinsider.com/FDA/Compass+Therapeutics+reports+phase+1+data+for+CTX-8371+at+ASCO+meeting/26536484.html Thu, 21 May 2026 17:00:26 -0400 A.50216726 CMPX O.21612337 O.49925668 http://www.streetinsider.com/FDA/Compass+Therapeutics+reports+phase+1+data+for+CTX-8371+at+ASCO+meeting/26536484.html <p>Compass Therapeutics Inc. (NASDAQ: CMPX) announced it will present phase 1 clinical data for CTX-8371 at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.</p> <p>The study evaluated CTX-8371, a dual checkpoint blocker targeting PD-1 and PD-L1, in 15 patients with advanced malignancies who had previously received immune checkpoint inhibitor treatment. Three patients achieved responses: one with triple-negative breast cancer showed greater than 90% reduction in target tumor lesions, one with Hodgkin lymphoma achieved a partial metabolic response, and one with non-small cell lung cancer achieved complete resolution of target lesions.</p> <p>At the two http://www.streetinsider.com/FDA/Compass+Therapeutics+reports+phase+1+data+for+CTX-8371+at+ASCO+meeting/26536484.html Thu, 21 May 2026 17:00:26 -0400 A.50216726 CMPX O.21612337 O.49925668 http://www.streetinsider.com/FDA/Compass+Therapeutics+reports+phase+1+data+for+CTX-8371+at+ASCO+meeting/26536484.html <p>Compass Therapeutics Inc. (NASDAQ: CMPX) announced it will present phase 1 clinical data for CTX-8371 at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.</p> <p>The study evaluated CTX-8371, a dual checkpoint blocker targeting PD-1 and PD-L1, in 15 patients with advanced malignancies who had previously received immune checkpoint inhibitor treatment. Three patients achieved responses: one with triple-negative breast cancer showed greater than 90% reduction in target tumor lesions, one with Hodgkin lymphoma achieved a partial metabolic response, and one with non-small cell lung cancer achieved complete resolution of target lesions.</p> <p>At the two http://www.streetinsider.com/FDA/Compass+Therapeutics+reports+phase+1+data+for+CTX-8371+at+ASCO+meeting/26536484.html Thu, 21 May 2026 17:00:26 -0400 A.50216726 CMPX O.21612337 O.49925668 http://www.streetinsider.com/FDA/Compass+Therapeutics+reports+phase+1+data+for+CTX-8371+at+ASCO+meeting/26536484.html <p>Compass Therapeutics Inc. (NASDAQ: CMPX) announced it will present phase 1 clinical data for CTX-8371 at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.</p> <p>The study evaluated CTX-8371, a dual checkpoint blocker targeting PD-1 and PD-L1, in 15 patients with advanced malignancies who had previously received immune checkpoint inhibitor treatment. Three patients achieved responses: one with triple-negative breast cancer showed greater than 90% reduction in target tumor lesions, one with Hodgkin lymphoma achieved a partial metabolic response, and one with non-small cell lung cancer achieved complete resolution of target lesions.</p> <p>At the two http://www.streetinsider.com/FDA/Compass+Therapeutics+reports+phase+1+data+for+CTX-8371+at+ASCO+meeting/26536484.html Thu, 21 May 2026 17:00:26 -0400 A.50216726 CMPX O.21612337 O.49925668 http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html <ul type="disc"><li style="margin-bottom:12pt;"><em>CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.</em></li><li style="margin-bottom:12pt;"><em>Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).</em></li><li style="margin-bottom:12pt;"><em>CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs).</em><br/><br/></li></ul> <p>BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 CMPX O.21612337 O.49925668 http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html <ul type="disc"><li style="margin-bottom:12pt;"><em>CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.</em></li><li style="margin-bottom:12pt;"><em>Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).</em></li><li style="margin-bottom:12pt;"><em>CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs).</em><br/><br/></li></ul> <p>BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 CMPX O.21612337 O.49925668 http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html <ul type="disc"><li style="margin-bottom:12pt;"><em>CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.</em></li><li style="margin-bottom:12pt;"><em>Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).</em></li><li style="margin-bottom:12pt;"><em>CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs).</em><br/><br/></li></ul> <p>BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 CMPX O.21612337 O.49925668 http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html <ul type="disc"><li style="margin-bottom:12pt;"><em>CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.</em></li><li style="margin-bottom:12pt;"><em>Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).</em></li><li style="margin-bottom:12pt;"><em>CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs).</em><br/><br/></li></ul> <p>BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 CMPX O.21612337 O.49925668 http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html <ul type="disc"><li style="margin-bottom:12pt;"><em>CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.</em></li><li style="margin-bottom:12pt;"><em>Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).</em></li><li style="margin-bottom:12pt;"><em>CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs).</em><br/><br/></li></ul> <p>BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 CMPX O.21612337 O.49925668 http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html <ul type="disc"><li style="margin-bottom:12pt;"><em>CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.</em></li><li style="margin-bottom:12pt;"><em>Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).</em></li><li style="margin-bottom:12pt;"><em>CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs).</em><br/><br/></li></ul> <p>BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 CMPX O.21612337 O.49925668 http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html <ul type="disc"><li style="margin-bottom:12pt;"><em>CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.</em></li><li style="margin-bottom:12pt;"><em>Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).</em></li><li style="margin-bottom:12pt;"><em>CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs).</em><br/><br/></li></ul> <p>BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 CMPX O.21612337 O.49925668 http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html <ul type="disc"><li style="margin-bottom:12pt;"><em>CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.</em></li><li style="margin-bottom:12pt;"><em>Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).</em></li><li style="margin-bottom:12pt;"><em>CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs).</em><br/><br/></li></ul> <p>BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Present+Promising+Phase+1+Clinical+Data+for+CTX-8371+in+Patients+with+Advanced+Malignancies+Treated+in+the+Post-Checkpoint+Inhibitor+Setting+at+the+2026+ASCO+Annual+Meeting/26536460.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 CMPX O.21612337 O.49925668 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Compass+Therapeutics%2C++++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26505307.html si-local-file:///var/storage/secattach/20260515/26505307.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Compass+Therapeutics%2C++++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26505307.html Fri, 15 May 2026 16:12:00 -0400 CMPX O.49925668 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Compass+Therapeutics%2C++++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26505307.html si-local-file:///var/storage/secattach/20260515/26505307.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Compass+Therapeutics%2C++++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26505307.html Fri, 15 May 2026 16:12:00 -0400 CMPX O.49925668 http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Participate+in+Upcoming+May+Investor+Events/26473025.html <p>BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of May.</p> <p align="left"><strong>Details are as follows:</strong></p> <p align="left"><strong>H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ </strong><br/><strong>Date:</strong> Tuesday, May 19, 2026 <br/><strong>Time:</strong> 1:30 PM ET<br/><strong>Webcast Link:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=hQkdpCsMJCzceS_rFSRRQUeZojyxoBc76XVkmgvFmF27Ug4oJbtLMbePNjlEUHaiHhiDkjjuRO2zGwEyW86JxF7NIEa32CNTpanAu9L_45Zz46VkP6FUY3AUTgHbzi7uhJKrPP_3MisSjbHhVzJlXoTDfCFfgz3MkqHxMycGW5n20KO375wKZ633R9UPhWvimCbl79DpH0kh7fbDAIJpMzvuHtUtxjr0v-18QheclrRrHRDZWrkpqZ2jFQaQnsHzUiyjIrzZNy-7fPA2Odd8Ew20eY2DswcfKo5r9EQphkMqKAVX11EQ06UtH60PjydP_xkot39Xk0QNVkb4PbJIjfYRvtSdkxSSSnAg-03Is1U3asiFIpoXOxHWTaXxEhUUISA-xsj7UwytDqtBNkNMH_7z1wuxZJrPVfk92ckBxAi-HSH_wy9YTnxVnYUWFjVXdaqADDLaTleUuzv0WG1_19tsCER3Wwi2g9u257iSfGt1Unk-LkwRTUiiHCr3uT-scfBEKgBGMFPYr6ZeTEZKaPdrFdbr7MR3t99NX1KSD74KoSdv6DcyrVvd1lm_58JT3ayF7kGoQFvOcqGDT57SDPM9PVLltBSB-G9SfPPT89YaHqfOIXO09b-fkHdy9wQArCeQkVIsD-Q3t2u5-NIu2kBEwnIQqSRY3Rl7_bOaxLQlY8Zim4x_kH-dP1RYV5gNe7dwyhRVgKE9egc6t-rwH3gkSjeYkPnO5FTIHPT3fG8J22RrPakBkuR5eygb1D3Y" rel="nofollow" target="_blank">https://journey.ct.events/view/bc55d2f9-d121-4f7d-8129-1f69f201bd7f</a></p> <p align="left"><strong>2026 Stifel Virtual Targeted Oncology Forum</strong><br/><strong>Date:</strong> Wednesday, May 20, 2026 <br/><strong>Time:</strong> 11:30 AM ET<br/><strong>Webcast Link:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=hQkdpCsMJCzceS_rFSRRQcdKxTOIZS-m8YFfRUvT7Fh9iszWVv5eg8rHNM0ZgKQ0EtSfdnfOAGVBCWsgvfo7ShikZwhFe5gliO_6kesjBZO28VaLMyq7lW39u2taZGnNz698zkQjH3oocJh95eNOOf9oMvztsWeTKImJotZlXAFD7g6HPezH_DCRZuOxerajc2MysbGl2XtvqOQ4Olc316WMdfi0c3G0ntBxpZ-tqB8ZAC-7r4hBzp-HPLD2RJUCJWwp1WBjEtg68Vl9YIw1HbJBmnecOCTe9YQD273ZF8xavhImSs4g51GGNOwzPZ5I75MjWoSZq2y7DyytLvDaWMBBWfPfbwdLdNFbeHNRXp26Toek-1HK3XdBa9EyrU3OzVMKdK7eAw1hyR0hyepzsGb2cbrv55jMvCVqxEnlJJeqHsoaE56VGh7VW3GhbpOATFRIDT3bk1XMZl7Ey4L-B1Q7BVzlBU1_4OVYODXFkL7G8xH-Z4hEhMcavcKXydlLwyACsqKCsfAv-wEOsoH9q9bPU8odzsfFp5Az0X3BDm_EofpUlRry18S6XS3oJsTpLOfJ7s03BgMM7GmnW0qedtssvDcLMx_fSZ5UIjcrGTzvtAjWul_pE853HIssfgv_JyPHAebvUkGiMjqVntzgPgH-l8wBq44QIs6oMv_sEVYSsFCAu6zupbq9uSD5bo6xh1qlHx8P9AdpRBxs7ydz8D0dxYwfms2g0OeURkJCsEWYwuJTLY56Llhs8MtudBZ-AOnUAZKGqHiB3Gp01B8dwaUEvloMsFRxrTQBhortZoU=" rel="nofollow" target="_blank">https://event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/QuhrzDf8Wdgui7i3FhuDb6</a></p> <p align="left"><strong>Virtual/Replay http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Participate+in+Upcoming+May+Investor+Events/26473025.html Tue, 12 May 2026 07:30:00 -0400 CMPX O.49925668 http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Participate+in+Upcoming+May+Investor+Events/26473025.html <p>BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of May.</p> <p align="left"><strong>Details are as follows:</strong></p> <p align="left"><strong>H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ </strong><br/><strong>Date:</strong> Tuesday, May 19, 2026 <br/><strong>Time:</strong> 1:30 PM ET<br/><strong>Webcast Link:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=hQkdpCsMJCzceS_rFSRRQUeZojyxoBc76XVkmgvFmF27Ug4oJbtLMbePNjlEUHaiHhiDkjjuRO2zGwEyW86JxF7NIEa32CNTpanAu9L_45Zz46VkP6FUY3AUTgHbzi7uhJKrPP_3MisSjbHhVzJlXoTDfCFfgz3MkqHxMycGW5n20KO375wKZ633R9UPhWvimCbl79DpH0kh7fbDAIJpMzvuHtUtxjr0v-18QheclrRrHRDZWrkpqZ2jFQaQnsHzUiyjIrzZNy-7fPA2Odd8Ew20eY2DswcfKo5r9EQphkMqKAVX11EQ06UtH60PjydP_xkot39Xk0QNVkb4PbJIjfYRvtSdkxSSSnAg-03Is1U3asiFIpoXOxHWTaXxEhUUISA-xsj7UwytDqtBNkNMH_7z1wuxZJrPVfk92ckBxAi-HSH_wy9YTnxVnYUWFjVXdaqADDLaTleUuzv0WG1_19tsCER3Wwi2g9u257iSfGt1Unk-LkwRTUiiHCr3uT-scfBEKgBGMFPYr6ZeTEZKaPdrFdbr7MR3t99NX1KSD74KoSdv6DcyrVvd1lm_58JT3ayF7kGoQFvOcqGDT57SDPM9PVLltBSB-G9SfPPT89YaHqfOIXO09b-fkHdy9wQArCeQkVIsD-Q3t2u5-NIu2kBEwnIQqSRY3Rl7_bOaxLQlY8Zim4x_kH-dP1RYV5gNe7dwyhRVgKE9egc6t-rwH3gkSjeYkPnO5FTIHPT3fG8J22RrPakBkuR5eygb1D3Y" rel="nofollow" target="_blank">https://journey.ct.events/view/bc55d2f9-d121-4f7d-8129-1f69f201bd7f</a></p> <p align="left"><strong>2026 Stifel Virtual Targeted Oncology Forum</strong><br/><strong>Date:</strong> Wednesday, May 20, 2026 <br/><strong>Time:</strong> 11:30 AM ET<br/><strong>Webcast Link:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=hQkdpCsMJCzceS_rFSRRQcdKxTOIZS-m8YFfRUvT7Fh9iszWVv5eg8rHNM0ZgKQ0EtSfdnfOAGVBCWsgvfo7ShikZwhFe5gliO_6kesjBZO28VaLMyq7lW39u2taZGnNz698zkQjH3oocJh95eNOOf9oMvztsWeTKImJotZlXAFD7g6HPezH_DCRZuOxerajc2MysbGl2XtvqOQ4Olc316WMdfi0c3G0ntBxpZ-tqB8ZAC-7r4hBzp-HPLD2RJUCJWwp1WBjEtg68Vl9YIw1HbJBmnecOCTe9YQD273ZF8xavhImSs4g51GGNOwzPZ5I75MjWoSZq2y7DyytLvDaWMBBWfPfbwdLdNFbeHNRXp26Toek-1HK3XdBa9EyrU3OzVMKdK7eAw1hyR0hyepzsGb2cbrv55jMvCVqxEnlJJeqHsoaE56VGh7VW3GhbpOATFRIDT3bk1XMZl7Ey4L-B1Q7BVzlBU1_4OVYODXFkL7G8xH-Z4hEhMcavcKXydlLwyACsqKCsfAv-wEOsoH9q9bPU8odzsfFp5Az0X3BDm_EofpUlRry18S6XS3oJsTpLOfJ7s03BgMM7GmnW0qedtssvDcLMx_fSZ5UIjcrGTzvtAjWul_pE853HIssfgv_JyPHAebvUkGiMjqVntzgPgH-l8wBq44QIs6oMv_sEVYSsFCAu6zupbq9uSD5bo6xh1qlHx8P9AdpRBxs7ydz8D0dxYwfms2g0OeURkJCsEWYwuJTLY56Llhs8MtudBZ-AOnUAZKGqHiB3Gp01B8dwaUEvloMsFRxrTQBhortZoU=" rel="nofollow" target="_blank">https://event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/QuhrzDf8Wdgui7i3FhuDb6</a></p> <p align="left"><strong>Virtual/Replay http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+to+Participate+in+Upcoming+May+Investor+Events/26473025.html Tue, 12 May 2026 07:30:00 -0400 CMPX O.49925668 http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Participate+in+Upcoming+May+Investor+Events/26473025.html <p>BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of May.</p> <p align="left"><strong>Details are as follows:</strong></p> <p align="left"><strong>H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ </strong><br/><strong>Date:</strong> Tuesday, May 19, 2026 <br/><strong>Time:</strong> 1:30 PM ET<br/><strong>Webcast Link:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=hQkdpCsMJCzceS_rFSRRQUeZojyxoBc76XVkmgvFmF27Ug4oJbtLMbePNjlEUHaiHhiDkjjuRO2zGwEyW86JxF7NIEa32CNTpanAu9L_45Zz46VkP6FUY3AUTgHbzi7uhJKrPP_3MisSjbHhVzJlXoTDfCFfgz3MkqHxMycGW5n20KO375wKZ633R9UPhWvimCbl79DpH0kh7fbDAIJpMzvuHtUtxjr0v-18QheclrRrHRDZWrkpqZ2jFQaQnsHzUiyjIrzZNy-7fPA2Odd8Ew20eY2DswcfKo5r9EQphkMqKAVX11EQ06UtH60PjydP_xkot39Xk0QNVkb4PbJIjfYRvtSdkxSSSnAg-03Is1U3asiFIpoXOxHWTaXxEhUUISA-xsj7UwytDqtBNkNMH_7z1wuxZJrPVfk92ckBxAi-HSH_wy9YTnxVnYUWFjVXdaqADDLaTleUuzv0WG1_19tsCER3Wwi2g9u257iSfGt1Unk-LkwRTUiiHCr3uT-scfBEKgBGMFPYr6ZeTEZKaPdrFdbr7MR3t99NX1KSD74KoSdv6DcyrVvd1lm_58JT3ayF7kGoQFvOcqGDT57SDPM9PVLltBSB-G9SfPPT89YaHqfOIXO09b-fkHdy9wQArCeQkVIsD-Q3t2u5-NIu2kBEwnIQqSRY3Rl7_bOaxLQlY8Zim4x_kH-dP1RYV5gNe7dwyhRVgKE9egc6t-rwH3gkSjeYkPnO5FTIHPT3fG8J22RrPakBkuR5eygb1D3Y" rel="nofollow" target="_blank">https://journey.ct.events/view/bc55d2f9-d121-4f7d-8129-1f69f201bd7f</a></p> <p align="left"><strong>2026 Stifel Virtual Targeted Oncology Forum</strong><br/><strong>Date:</strong> Wednesday, May 20, 2026 <br/><strong>Time:</strong> 11:30 AM ET<br/><strong>Webcast Link:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=hQkdpCsMJCzceS_rFSRRQcdKxTOIZS-m8YFfRUvT7Fh9iszWVv5eg8rHNM0ZgKQ0EtSfdnfOAGVBCWsgvfo7ShikZwhFe5gliO_6kesjBZO28VaLMyq7lW39u2taZGnNz698zkQjH3oocJh95eNOOf9oMvztsWeTKImJotZlXAFD7g6HPezH_DCRZuOxerajc2MysbGl2XtvqOQ4Olc316WMdfi0c3G0ntBxpZ-tqB8ZAC-7r4hBzp-HPLD2RJUCJWwp1WBjEtg68Vl9YIw1HbJBmnecOCTe9YQD273ZF8xavhImSs4g51GGNOwzPZ5I75MjWoSZq2y7DyytLvDaWMBBWfPfbwdLdNFbeHNRXp26Toek-1HK3XdBa9EyrU3OzVMKdK7eAw1hyR0hyepzsGb2cbrv55jMvCVqxEnlJJeqHsoaE56VGh7VW3GhbpOATFRIDT3bk1XMZl7Ey4L-B1Q7BVzlBU1_4OVYODXFkL7G8xH-Z4hEhMcavcKXydlLwyACsqKCsfAv-wEOsoH9q9bPU8odzsfFp5Az0X3BDm_EofpUlRry18S6XS3oJsTpLOfJ7s03BgMM7GmnW0qedtssvDcLMx_fSZ5UIjcrGTzvtAjWul_pE853HIssfgv_JyPHAebvUkGiMjqVntzgPgH-l8wBq44QIs6oMv_sEVYSsFCAu6zupbq9uSD5bo6xh1qlHx8P9AdpRBxs7ydz8D0dxYwfms2g0OeURkJCsEWYwuJTLY56Llhs8MtudBZ-AOnUAZKGqHiB3Gp01B8dwaUEvloMsFRxrTQBhortZoU=" rel="nofollow" target="_blank">https://event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/QuhrzDf8Wdgui7i3FhuDb6</a></p> <p align="left"><strong>Virtual/Replay http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Participate+in+Upcoming+May+Investor+Events/26473025.html Tue, 12 May 2026 07:30:00 -0400 CMPX O.49925668 http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Participate+in+Upcoming+May+Investor+Events/26473025.html <p>BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of May.</p> <p align="left"><strong>Details are as follows:</strong></p> <p align="left"><strong>H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ </strong><br/><strong>Date:</strong> Tuesday, May 19, 2026 <br/><strong>Time:</strong> 1:30 PM ET<br/><strong>Webcast Link:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=hQkdpCsMJCzceS_rFSRRQUeZojyxoBc76XVkmgvFmF27Ug4oJbtLMbePNjlEUHaiHhiDkjjuRO2zGwEyW86JxF7NIEa32CNTpanAu9L_45Zz46VkP6FUY3AUTgHbzi7uhJKrPP_3MisSjbHhVzJlXoTDfCFfgz3MkqHxMycGW5n20KO375wKZ633R9UPhWvimCbl79DpH0kh7fbDAIJpMzvuHtUtxjr0v-18QheclrRrHRDZWrkpqZ2jFQaQnsHzUiyjIrzZNy-7fPA2Odd8Ew20eY2DswcfKo5r9EQphkMqKAVX11EQ06UtH60PjydP_xkot39Xk0QNVkb4PbJIjfYRvtSdkxSSSnAg-03Is1U3asiFIpoXOxHWTaXxEhUUISA-xsj7UwytDqtBNkNMH_7z1wuxZJrPVfk92ckBxAi-HSH_wy9YTnxVnYUWFjVXdaqADDLaTleUuzv0WG1_19tsCER3Wwi2g9u257iSfGt1Unk-LkwRTUiiHCr3uT-scfBEKgBGMFPYr6ZeTEZKaPdrFdbr7MR3t99NX1KSD74KoSdv6DcyrVvd1lm_58JT3ayF7kGoQFvOcqGDT57SDPM9PVLltBSB-G9SfPPT89YaHqfOIXO09b-fkHdy9wQArCeQkVIsD-Q3t2u5-NIu2kBEwnIQqSRY3Rl7_bOaxLQlY8Zim4x_kH-dP1RYV5gNe7dwyhRVgKE9egc6t-rwH3gkSjeYkPnO5FTIHPT3fG8J22RrPakBkuR5eygb1D3Y" rel="nofollow" target="_blank">https://journey.ct.events/view/bc55d2f9-d121-4f7d-8129-1f69f201bd7f</a></p> <p align="left"><strong>2026 Stifel Virtual Targeted Oncology Forum</strong><br/><strong>Date:</strong> Wednesday, May 20, 2026 <br/><strong>Time:</strong> 11:30 AM ET<br/><strong>Webcast Link:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=hQkdpCsMJCzceS_rFSRRQcdKxTOIZS-m8YFfRUvT7Fh9iszWVv5eg8rHNM0ZgKQ0EtSfdnfOAGVBCWsgvfo7ShikZwhFe5gliO_6kesjBZO28VaLMyq7lW39u2taZGnNz698zkQjH3oocJh95eNOOf9oMvztsWeTKImJotZlXAFD7g6HPezH_DCRZuOxerajc2MysbGl2XtvqOQ4Olc316WMdfi0c3G0ntBxpZ-tqB8ZAC-7r4hBzp-HPLD2RJUCJWwp1WBjEtg68Vl9YIw1HbJBmnecOCTe9YQD273ZF8xavhImSs4g51GGNOwzPZ5I75MjWoSZq2y7DyytLvDaWMBBWfPfbwdLdNFbeHNRXp26Toek-1HK3XdBa9EyrU3OzVMKdK7eAw1hyR0hyepzsGb2cbrv55jMvCVqxEnlJJeqHsoaE56VGh7VW3GhbpOATFRIDT3bk1XMZl7Ey4L-B1Q7BVzlBU1_4OVYODXFkL7G8xH-Z4hEhMcavcKXydlLwyACsqKCsfAv-wEOsoH9q9bPU8odzsfFp5Az0X3BDm_EofpUlRry18S6XS3oJsTpLOfJ7s03BgMM7GmnW0qedtssvDcLMx_fSZ5UIjcrGTzvtAjWul_pE853HIssfgv_JyPHAebvUkGiMjqVntzgPgH-l8wBq44QIs6oMv_sEVYSsFCAu6zupbq9uSD5bo6xh1qlHx8P9AdpRBxs7ydz8D0dxYwfms2g0OeURkJCsEWYwuJTLY56Llhs8MtudBZ-AOnUAZKGqHiB3Gp01B8dwaUEvloMsFRxrTQBhortZoU=" rel="nofollow" target="_blank">https://event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/QuhrzDf8Wdgui7i3FhuDb6</a></p> <p align="left"><strong>Virtual/Replay http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+to+Participate+in+Upcoming+May+Investor+Events/26473025.html Tue, 12 May 2026 07:30:00 -0400 CMPX O.49925668 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Compass+Therapeutics%2C+++++For%3A+Mar+31/26430295.html si-local-file:///var/storage/secattach/20260505/26430295.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Compass+Therapeutics%2C+++++For%3A+Mar+31/26430295.html Tue, 05 May 2026 08:01:00 -0400 CMPX O.49925668 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Compass+Therapeutics%2C+++++For%3A+Mar+31/26430295.html si-local-file:///var/storage/secattach/20260505/26430295.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Compass+Therapeutics%2C+++++For%3A+Mar+31/26430295.html Tue, 05 May 2026 08:01:00 -0400 CMPX O.49925668